Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 55 years of age~* Diagnosis of multiple sclerosis (MS)~* Relapsing MS: relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS)~* At least 1 relapse during the previous 1 year or 2 relapses during the previous 2 years or a positive gadolinium-enhancing MRI scan in previous year~* Expanded disability status scale (EDSS) score of 0 to 5.5~Exclusion Criteria:~* Primary progressive MS~* Disease duration of more than 10 years in patients with an EDSS score of 2 or less~* Patients with an active chronic disease of the immune system other than MS~* Patients at risk of developing or having reactivation of hepatitis~* Patients with active systemic infections or with neurological findings consistent with PML

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- OMB 20 mg (Type: EXPERIMENTAL): Ofatumumab 20 mg pre-filled syringes for subcutaneous injectionon on days 1 ,7 ,14, week 4 and every 4 weeks thereafter and a teriflunomide- matching placebo, taken orally once daily
- TER 14 mg (Type: ACTIVE_COMPARATOR): Teriflunomide 14 mg oral capsule taken once daily and matching placebo for subcutaneous injections to ofatumumab on days 1, 7, 14, week 4 and every 4 weeks thereafter

Based on this trial design, predict the completion outcome and termination type (if applicable).